Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 975 of 6351
-
New combo therapy aims to stop small liver cancers from coming back
Disease control OngoingFollowing the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a promising treatment option for patients with HCC. In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a metastatic mechanism encourages exploring adjuv…
Phase 2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New combo therapy shows promise for tough lung cancer
Disease control OngoingA Phase II Multicenter, Open-Label, Single Arm Study to Determine the Efficacy, Safety and Tolerability of AZD2811 and Durvalumab Combination as Maintenance Therapy After Induction with Platinum-Based Chemotherapy Combined with Durvalumab, for the First-Line Treatment of Patients…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Promising drug combo slows advanced prostate cancer in major trial
Disease control CompletedThe purpose of the study is to assess the efficacy and safety of darolutamide in combination with standard androgen deprivation therapy (ADT) in patients with metastatic hormone sensitive prostate cancer.
Phase 3 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug cocktail aims to slow prostate cancer spread
Disease control Recruiting nowBackground: Metastatic castration sensitive and castration resistant prostate cancer (mCSPC and mCRPC) are prostate cancers that have spread to other parts of the body. Use of the drug docetaxel with androgen deprivation therapy can improve survival for men with mCSPC. Researche…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New combo therapy aims to stall pancreatic cancer in BRCA patients
Disease control OngoingThis phase II trial studies whether adding pembrolizumab to olaparib (standard of care) works better than olaparib alone in treating patients with pancreatic cancer with germline BRCA1 or BRCA2 mutations that has spread to other places in the body (metastatic). BRCA1 and BRCA2 ar…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Poop pills plus immunotherapy: new hope for colorectal cancer patients?
Disease control OngoingThis phase II trial studies the effect of fecal microbiota transplant and re-introduction of anti-PD-1 therapy (pembrolizumab or nivolumab) in treating anti-PD-1 non-responders with colorectal cancer that has spread to other places in the body (metastatic). Fecal microbiota trans…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New trial aims to tame transplant complications in blood cancer patients
Disease control Recruiting nowA multi-centre phase II trial of GvHD prophylaxis following unrelated donor stem cell transplantation comparing Thymoglobulin vs. Calcineurin inhibitor or Sirolimus-based post-transplant cyclophosphamide.
Phase 2 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Can antimalarials be safely used in early pregnancy? a massive registry seeks answers
Knowledge-focused CompletedThe MiMBa (Malaria in Mothers and Babies) Pregnancy Registry aims to generate robust evidence on the safety of a range of antimalarials when used in pregnancy, particularly in the first trimester. This will be a multi-country observational study and will be deployed in several fi…
Sponsor: Liverpool School of Tropical Medicine • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
New hope for Hard-to-Treat myeloma: teclistamab trial in japan
Disease control CompletedThe purpose of the study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (RRMM) at the recommended Phase 2 dose (RP2D) identified in Study 64007957MMY1001 (NCT03145181) in Phase 1 part and to evaluate the efficacy o…
Phase 1/2 • Sponsor: Janssen Pharmaceutical K.K. • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New drug combo offers hope for older AML patients who Can't tolerate chemo
Disease control OngoingThis phase II trial studies the possible benefits of venetoclax and ASTX727 in treating patients with acute myeloid leukemia that has come back (relapsed) or does not respond to treatment (refractory), or elderly patients with newly diagnosed acute myeloid leukemia who are not ca…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
AI-Powered MRI could eliminate need for brain tumor biopsies
Diagnosis Recruiting nowGlioma is a tumor of the central nervous system. These lesions are sorted with the WHO ranking regarding the tumoral oncotype. The tumoral MRI assessment is the first step before any medical decision. Currently, only anatomical biopsy can give the tumor grade definition and help …
Sponsor: Poitiers University Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:30 UTC
-
New combo treatment aims to tackle deadly brain tumors
Disease control Recruiting nowThe purpose of this study is to evaluate the treatment regimen of using Laser Interstitial Thermal Therapy (LITT) and Hypo-fractionated Radiation Therapy to treat patients with newly diagnosed gliomas.
Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to outsmart tough blood cancer
Disease control Recruiting nowThe purpose of this study is to find out whether the combination treatment of romidepsin and oral azacytidine is safe and effective in patients with Peripheral T-Cell Lymphoma (PTCL). This study will compare the experimental combination treatment of romidepsin and oral azacytidin…
Phase 2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Daily pill shows promise for Long-Term migraine prevention
Prevention CompletedThis study will evaluate the Long-Term Safety and Tolerability of Atogepant 60 mg daily for the Prevention of Migraine in Participants with Chronic or Episodic Migraine
Phase 3 • Sponsor: AbbVie • Aim: Prevention
Last updated Jun 27, 2026 08:05 UTC
-
Spinal cord stimulation: a surprising key to unlocking metabolism?
Knowledge-focused Recruiting nowThe objective of this study is to investigate and utilize spinal cord stimulation (SCS) as an effective approach to eliciting weight loss and potentially alleviating Type 2 diabetes mellitus (DM), as evidenced by increasing metabolism of adipose tissue.
Sponsor: Oregon Health and Science University • Aim: Knowledge-focused
Last updated Aug 27, 2026 00:00 UTC
-
Experimental drug targets root cause of rare muscle-wasting disease
Disease control OngoingBBP-418 is being developed for the treatment of patients with Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I). This is an open label study to determine the safety and tolerability of ascending dose levels of BBP-418 in the treatment of ambulatory and non-ambulatory patients with …
Phase 2 • Sponsor: ML Bio Solutions, Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Acupuncture vs. sham needles: a test for chemo nerve damage
Symptom relief CompletedThe purpose of this study is to assess the neurological efficacy of acupuncture in patients with cancer who experienced peripheral neuropathy, which is induced by chemotherapy.
Sponsor: China Medical University Hospital • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Poop pills could supercharge cancer immunotherapy
Disease control CompletedRenal cell carcinoma (RCC) is the sixth most common cancer in men and the eighth in women in the USA. In Italy RCC incidence was 11500 new cases in 2017, while mortality was 3371 cases in 2015. Increasing evidence suggests that response to immune checkpoint inhibitors (ICIs), a n…
Phase 1/2 • Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Disease control
Last updated Jun 26, 2026 14:54 UTC
-
Can Trauma-Focused coping skills boost HIV suppression in women?
Disease control CompletedImpACT+ (Improving AIDS Care after Trauma+), is an individual-level coping intervention to address traumatic stress and HIV care engagement among South African women with sexual trauma histories. We propose a full-scale randomized controlled trial to examine the effect of ImpACT+…
Sponsor: Columbia University • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New Pump-Delivered Parkinson's drug shows promise in Long-Term safety trial
Disease control CompletedParkinson's disease (PD) is a neurological condition, which affects the brain. PD gets worse over time, but how quickly it progresses varies a lot from person to person. Some symptoms of PD are tremors, stiffness, and slowness of movement. This study will assess how safe and effe…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC